United States Patent 5,849,911: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
United States Patent 5,849,911, titled "Antivirally Active Heterocyclic Azahexane Derivatives," was granted to Novartis Finance Corporation on December 15, 1998. This patent is significant in the field of antiviral medications, particularly for the treatment of HIV. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.
Background and Inventors
The patent was filed by a team of inventors including Alexander Fässler, Guido Bold, Hans-Georg Capraro, Marc Lang, and Satish Chandra Khanna, representing Novartis Finance Corporation. The application was submitted on April 9, 1997, with priority dates tracing back to April 22, 1996, and January 31, 1997, in Switzerland[4].
Scope of the Invention
The patent focuses on novel compounds known as heterocyclic azahexane derivatives, which exhibit high inhibitory activity against viruses, particularly HIV. These compounds are designed to have improved pharmacokinetics, such as high bioavailability and selectivity. The invention encompasses a broad range of chemical structures and their applications in antiviral therapy[4].
Claims of the Patent
The patent includes multiple claims that define the scope of the invention. Here are some key claims:
- Compound Claims: The patent claims various heterocyclic azahexane derivatives with specific chemical structures. These compounds are characterized by their R groups, which can include lower alkoxycarbonyl, secondary or tertiary lower alkyl, or lower alkylthio lower alkyl, among others[4].
- Pharmaceutical Compositions: Claims also cover pharmaceutical compositions containing these compounds, which are formulated for administration to treat viral infections[4].
- Methods of Treatment: The patent claims methods of treating viral infections, particularly HIV, using the described compounds[4].
Detailed Description of the Invention
The patent provides a detailed description of the chemical structures, synthesis methods, and pharmacological properties of the heterocyclic azahexane derivatives. It outlines the specific R groups and their substitutions, which are crucial for the antiviral activity of these compounds. The description also includes examples of how these compounds can be synthesized and their bioavailability and selectivity profiles[4].
Patent Landscape Analysis
Defining Scope and Keywords
To analyze the patent landscape around U.S. Patent 5,849,911, one must first define the scope and relevant keywords. Key terms include "heterocyclic azahexane derivatives," "antiviral compounds," "HIV treatment," and "pharmaceutical compositions."
Searching and Organizing Patents
Using patent databases, one can search for patents related to these keywords. Organizing these patents by filing date, assignee, and technology subcategories helps in understanding the evolution and distribution of innovations in this field[3].
Identifying Trends and Key Players
The analysis reveals trends in patent filings, such as an increase in antiviral compound patents in the late 1990s and early 2000s. Key players include pharmaceutical companies like Novartis, Pfizer, and Gilead Sciences, which have been actively involved in developing antiviral therapies[3].
Analyzing Citations and Evolution
Studying the citations and references within the patent and related patents provides insights into the development and impact of these compounds. For example, U.S. Patent 5,849,911 references earlier patents and publications by the inventors, indicating a continuous research effort in this area[4].
Generating Insights for Decisions
The analysis offers practical guidance for strategic decisions. For instance, it helps in evaluating the competitive landscape, identifying potential legal vulnerabilities, and understanding the strength of patent portfolios in the antiviral drug market[3].
Key Players and Innovations
Novartis Finance Corporation
As the assignee of U.S. Patent 5,849,911, Novartis has been a significant player in the development of antiviral therapies. The company's research efforts have led to several innovations in this field, contributing to the broader patent landscape.
Other Pharmaceutical Companies
Companies like Pfizer and Gilead Sciences have also made substantial contributions to antiviral drug development. Their patents and innovations have shaped the market and influenced the direction of research in this area.
Technological Trends
The late 1990s and early 2000s saw a surge in the development of antiviral compounds, particularly those targeting HIV. This period was marked by significant advancements in understanding the virus and developing effective treatments.
Legal and Litigation Aspects
U.S. Patent 5,849,911 has been involved in various legal proceedings, including Patent Trial and Appeal Board (PTAB) cases. These cases highlight the importance of patent protection and the competitive nature of the pharmaceutical industry[5].
Impact on the Pharmaceutical Industry
The invention described in U.S. Patent 5,849,911 has had a notable impact on the pharmaceutical industry. It has contributed to the development of more effective antiviral therapies and has influenced subsequent research in this area.
"A patent landscape analysis offers insights into ongoing innovations by revealing information about patent filings within a specific technological domain, offering a present picture and a prediction about technological trends, key players, and new and exciting innovations."[3]
Conclusion
U.S. Patent 5,849,911 is a pivotal invention in the field of antiviral medications, particularly for HIV treatment. The detailed analysis of its scope, claims, and the broader patent landscape provides valuable insights into the technological trends, key players, and legal aspects of the pharmaceutical industry.
Key Takeaways
- Novel Compounds: The patent introduces novel heterocyclic azahexane derivatives with high antiviral activity.
- Pharmaceutical Applications: These compounds are formulated into pharmaceutical compositions for treating viral infections.
- Key Players: Novartis, Pfizer, and Gilead Sciences are significant players in the antiviral drug market.
- Technological Trends: The late 1990s and early 2000s saw a surge in antiviral compound development.
- Legal Aspects: The patent has been involved in various legal proceedings, highlighting the importance of patent protection.
FAQs
What is the main focus of U.S. Patent 5,849,911?
The main focus of U.S. Patent 5,849,911 is on novel heterocyclic azahexane derivatives with high antiviral activity, particularly against HIV.
Who are the inventors of U.S. Patent 5,849,911?
The inventors include Alexander Fässler, Guido Bold, Hans-Georg Capraro, Marc Lang, and Satish Chandra Khanna.
What is the significance of this patent in the pharmaceutical industry?
This patent has contributed significantly to the development of effective antiviral therapies and has influenced subsequent research in this area.
Which companies are key players in the antiviral drug market?
Key players include Novartis, Pfizer, and Gilead Sciences.
What legal proceedings has U.S. Patent 5,849,911 been involved in?
The patent has been involved in various PTAB cases, highlighting the competitive nature of the pharmaceutical industry.
Sources
- United States Patent (19) - googleapis.com: Fissler et al. USOO.584991-1A 11 Patent Number: 5,849,911.
- Regulations.gov: Patent extension application 5,849,911 for Reyataz (atazanavir sulfate).
- Goldstein Patent Law: How to Do Patent Landscape Analysis.
- Patent Images Storage: United States Patent (19) - googleapis.com.
- Law360: U.S. Patent Number 5,849,911 : Ptab Cases :: Law360.
